Year End Update

RNS Number : 4096Y

Venn Life Sciences Holdings PLC

03 March 2017

 

3 March 2017

Venn Life Sciences Holdings Plc

("Venn Life Sciences" or the "Company")

Year End Update

Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations, today provides the following update.

2016 represented another year of strong growth for Venn with sales in excess of €18m (2015 €11m). The business finished 2016 with a strong cash position of €3m (€1.75m 30 June 2016). The strong momentum enjoyed by the business in 2016 has continued into 2017 todate, with new business contracts signed to the value €5.7m in the first two months of the year.

Enquiries:

Venn Life Sciences Holdings Plc
Tony Richardson, Chief Executive Officer			Tel: [phone]
Davy (Nominated Adviser, ESM Adviser and Joint Broker)
Fergal Meegan / Matthew de Vere White (Corporate Finance)				Tel: [phone]
Hybridan LLP (Co-Broker)
Claire Louise Noyce			Tel: [phone]
Walbrook PR Ltd		Tel: [phone] or [e-mail]
Paul McManus			Mob: [phone]
Lianne Cawthorne			Mob: [phone]

About Venn Life Sciences:

Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects.

 

END

 

 

TSTSSWFWEFWSEID